Home


Login | Forgot password?
September 3, 2010
A new path to hope

Brainsgate is a medical device company committed to developing a novel treatment modality, electrical SPG stimulation. This platform technology has been shown to increase blood flow to the brain and as a result has broad potential for treating central nervous system disorders. BrainsGate is currently focusing on:

1. Improve the outcome of patients suffering from ischemic stroke, in a 24 hour window after onset of symptoms.

2. Long-term SPG stimulation for the treatment of vascular dementia patients.


Focus: ISS
BrainsGate's product for the treatment of ischemic stroke and vascular dementia read more
Focus: Stroke
The leading cause of adult long-term disability and the third leading cause of death read more
October 13, 2009
ImpACT-24 at Central DuPage Hosital
National Investigational Trial for Emergency Stroke Care At CDH: One Illinois Hospital Tests New Device That May Reverse Brain Damage Up to 24 Hours After Stroke > full story
September 25, 2008
BrainsGate launches ImpACT-24
ImpACT-24 is a randomized, sham-controlled, double blind study to test the safety and efficacy of BrainsGate's ISS for treatment of acute ischemic stroke victims in a 24 hour window > full story